Solid Biosciences (SLDB) EBIT (2017 - 2026)

Solid Biosciences has disclosed EBIT across 10 years of filings, most recently posting -$57.3 million for Q1 2026.

• EBIT for Q1 2026 came in at -$57.3 million, down 43.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$196.5 million (down 37.46% YoY), and the FY2025 annual result was -$179.2 million, down 38.14% from the prior year.
• EBIT came in at -$57.3 million for Q1 2026 at Solid Biosciences, down from -$49.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$21.1 million in Q3 2022 to a low of -$57.3 million in Q1 2026.
• The 5-year median for EBIT is -$32.0 million (2023), against an average of -$33.9 million.
• Across the five-year window, EBIT slumped 85.32% in 2022 and jumped 35.59% in 2023, its largest moves.
• Solid Biosciences' EBIT stood at -$34.6 million in 2022, then surged by 35.59% to -$22.3 million in 2023, then plunged by 79.19% to -$39.9 million in 2024, then fell by 23.83% to -$49.4 million in 2025, then fell by 16.0% to -$57.3 million in 2026.
• The last three EBIT figures came in at -$57.3 million (Q1 2026), -$49.4 million (Q4 2025), and -$48.1 million (Q3 2025), per Business Quant data.